|
(b)(4).Additional information was requested, and the following was obtained: lot number? sabbhqs0.The following information was requested, but unavailable: what tissue was the suture used on? unknown.What was the name of the procedure? unknown.Did the needle pull off during the procedure? unknown.Was the needle removed from the patient? unknown.Was there any patient consequence or injury? unknown.What was being done when the needle pulled-off (removal from package / during passage through tissue)? unknown.Procedure name and date? unknown.Event date? unknown.This is a combination product, and the event has been reviewed for both the suture and the triclosan.Trade name - irgacare®, active ingredient(s) ¿ triclosan, dosage form ¿ suture/solid/parenteral, strength ¿ = 275 ¿g/m.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.
|
|
Product complaint # (b)(4).Date sent to the fda: 6/1/2022.This is a combination product, and the event has been reviewed for both the suture and the triclosan.This report is being submitted pursuant to the provisions of 21 cfr, part 803, part 4 subpart b.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by ethicon, or its employees that the report constitutes an admission that the product, ethicon, or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.H6 component code: g07002 no device problem found.A manufacturing record evaluation was performed for the finished device lot, and no non-conformances were identified.H3 investigational summary: twenty-four packets of product code vcp398h were returned to ethicon for analysis with the packaging closed.Upon initial inspection, of the samples, no external damage was observed on the packets.In order to evaluate the conditions of the returned samples, thirteen packets were opened, and no defects were detected.The swage and attachment area were noted to be as expected.The sutures were dispensed without problems and examined along the strands to detect any issues related to no defects observed during evaluation.Functional test was performed, and the pull force result were above the minimum requirements.The event described could not be confirmed as the device performed without any defect noted.As part of our quality process, the manufacturing records of this lot-serial number were reviewed, and the manufacturing standards were met prior to the release of this batch.It should be noted that as part of our quality process, each batch is randomly inspected and functionally tested during manufacturing to ensure the device meets the required specifications prior to shipment.Additional complaint information monitoring for potential safety signals is conducted through complaint trending as part of post-market surveillance.Trade name - irgacare® active ingredient(s) ¿ triclosan.Dosage form ¿ suture/solid/parenteral.Strength ¿ = 275 g/m.
|